Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 7 | Journal of Translational Medicine

Fig. 7

From: Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancers

Fig. 7

Microfluidic chip-based analyses of nivolumab-mediated effects on immune cell migration and cytokine release towards TMPRSS2high cells. A, B: During a 3-day period, immune cells significantly infiltrated toward TMPRSS2high MCF-7 cells (A), but not to TMPRSS2low cells (B) treated with nivolumab. C, D. Representative immunofluorescent images of day 3 cancer cells, TMPRSS2high (C) and TMPRSS2low (D) marked in red, lymphocytes in blue and apoptotic cells in green. E: Percentage of apoptotic cells of TMPRSS2high/vector MCF-7 cells. Nivolumab therapy on immune cells showed a marginally higher apoptosis rate in TMPRSS2high compared to TMPRSS2low cells. F: Higher release of IL-2 and reduced CCL2 and CCL3 levels in TMPRSS2high MCF-7 cells when compared to mock-transfected cells. CI - Cancer cells co-cultured with Immune cells, CIN – CI treated with nivolumab

Back to article page